Atherogenic Index of Plasma (AIP) a Tool to Assess Changes in Cardiovascular Disease Risk Post Laparoscopic Sleeve Gastrectomy. (3rd August 2020)

• Record Type: Journal Article
• Authors: Al Shawaf, Eman; Al-Ozairi, Ebaa; Al-Asfar, Fahad; Mohammad, Anwar; Al-Beloushi, Shaima; Devarajan, Sriraman; Al-Mulla, Fahd; Abubaker, Jehad; Arefanian, Hossein
• Other Names: De Lucia Claudio Academic Editor.
• Is Part Of: Journal of diabetes research. Volume 2020(2020)
• Publication Date: 2020-08-03
• Subjects: Diabetes -- Periodicals; Diabetes -- Pathophysiology -- Periodicals; Diabetes -- Prevention -- Periodicals; Diabetes -- Etiology -- Periodicals; Diabetes -- Epidemiology -- Periodicals; Diabetes -- Pathogenesis -- Periodicals; 616.462005
• DOI: 10.1155/2020/2091341
• Languages: English
• ISSNs: 2314-6745

Abstract

Abstract : Predictive indices like the atherogenic index of plasma (AIP) have been developed to estimate the risk of cardiovascular disease (CVD). Metabolic surgery is the most effective treatment for a rapid improvement of morbid obesity and its comorbidities such as type 2 diabetes (T2D) and CVD. A decreased reoccurrence of CVD after metabolic surgery has been reported by several studies. However, studies utilizing predictive indices for CVD risk in CVD-free morbid-obese patients who undertook laparoscopic sleeve gastrectomy (LSG) are lacking. Here, we use AIP as a tool to evaluate the improvement in CVD risk post-LSG in morbid-obese people who had no history of CVD. Method. We compared baseline, 6- and 12-month post-LSG score of AIP, vascular age, circulating biochemical markers related to CVD in two groups of BMI and age-matched morbid-obese participants with and without T2D. Results. At baseline, people with T2D had significantly higher AIP both, with morbid obesity (0.23 ± 0.06, p < 0.001 ) and normal weight (0.022 ± 0.05, p < 0.001 ) compared to their BMI-matched without T2D group. People with morbid obesity had low AIP (− 0.083 ± 0.06 ). Vascular age was significantly higher in people with morbid obesity and T2D (65.8 ± 3.7 year, p < 0.0001 ) compared to morbid obesity (37.9 ± 2.6 year). After one year, AIP was significantly reduced compared to baseline score in people with morbid obesity with/without T2D, respectively (− 0.135 ± 0.07, p = 0.003 ; and − 0.36 ± 0.04, p = 0.0002 ). Conclusion . Our data illuminates AIP as a reliable predictive index for CVD risk in morbid-obese people who had no history of CVD. Moreover, AIP accurately distinguishes between morbid obesity with T2D and morbid obesity and showed a rapid and significant reduction in CVD risk after LSG in people who had no history of CVD. This is a ClinicalTrials.gov registered trial (Reference NCT03038373 ).